Ranking reveals biopharma’s most innovative companies

IDEA Pharma’s 12th index finds that Pfizer and AstraZeneca reign supreme again.

By Taren Grom • June 7, 2023

Janssen and Legend’s longtime collaboration lands a CAR-T win at ASCO

A partnership going on six years between the pharma giant and the Chinese biotech is showing that their CAR-T cell therapy for multiple myeloma is highly effective.

By Michael Gibney • June 5, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

A key to ‘winning’ in today’s market — and other trends pharma leaders are tracking

Healthcare pros share the market drivers they believe are having the biggest impact on the industry.

By Taren Grom • June 2, 2023

Woman of the Week: Mirati Therapeutics’ Laurie Stelzer

With the recent approval of Krazati, the biotech veteran is guiding Mirati into its next phase as a commercial organization.

By Taren Grom • May 31, 2023

CVS is exiting clinical trials. Does this spell trouble for retail-based research?

Walgreens leaders are not deterred and hope to fill the holes left behind by the pharmacy giant.

By Kelly Bilodeau • May 30, 2023

The cell ‘atlasing’ approach pushing the limits of drug discovery

Vizgen’s CEO discusses the potential of spatial genomics in the life sciences and the company’s role in the movement.

By Taren Grom • May 24, 2023

Woman of the Week: Cognition Therapeutics’ Lisa Ricciardi

As CEO of the neurogenerative company, Ricciardi is applying her decades of “human capital” to advance Alzheimer’s and dementia treatments.

By Taren Grom • May 24, 2023

Biotechs blast experiments into space

Conducting life sciences research in space’s microgravity could have far-ranging implications for drug development on Earth.

By Alexandra Pecci • May 23, 2023

The power of genetics — how research into gene sequencing could revolutionize biopharma

Ancient DNA from a deer tooth. A new way to connect genes with disease. Biological super-computing. These genetic advances could play a part in our biopharma future.

By Michael Gibney • May 23, 2023

Amid surging Duchenne market, Capricor touts potential ‘backbone’ therapy of the space

The company's CEO on the vital role its late-stage candidate could play in the lives of DMD patients. 

By Kelly Bilodeau • May 22, 2023

What pharma can teach biotech about the life cycle management of a drug

Global product teams are common in pharma but have yet to gain traction in biotech. Here's why this model can work.

By Dr. Stephen Dale and Kathleen Ford • May 18, 2023

Biden’s pick to lead the NIH faces an uphill battle

Pending Senate confirmation, NCI head Monica Bertagnolli will take the helm of the collection of research organizations as it faces increasing bipartisan scrutiny. 

By Karissa Waddick • May 18, 2023

A day in the life of a pharma exec: Lyndra’s Patricia Hurter

How the CEO starts each day with a ride on one of her horses, reduces daily meetings and uses her network to get through crises like the SVB Bank collapse.

By Meagan Parrish • May 17, 2023

From farm to pharma: How cows could play a role in the next flu breakthrough

SAb Biotherapeutics is working on a novel product that uses cow antibodies genetically engineered into human antibodies to prevent and treat infectious diseases.

By Alexandra Pecci • May 16, 2023

Years into the pandemic, only a handful of clinical trials are targeting long COVID — here’s one of them

Scientists at Stanford are testing Pfizer’s Paxlovid on long COVID symptoms and their efforts could provide clues for other conditions.  

By Kelly Bilodeau • May 15, 2023

How pharma’s rocky real estate market has changed — for better and worse

Whether you’re looking to build a new site or expand lab space, here are the biggest trends impacting life sciences real estate.

By Karissa Waddick • May 11, 2023

AbbVie’s Christopher Boone on RWE’s potential — and its ‘profound ethical dilemmas’

With decades of experience in public health, Boone is leveraging RWE to move the needle within clinical development.

By Taren Grom • May 10, 2023

Woman of the Week: Reneo Pharmaceuticals’ Ashley Hall

After ushering a blockbuster to market, the chief development officer is channeling her experience into the rare disease space.

By Taren Grom • May 10, 2023

This ‘hot-blooded’ CEO is aiming to transform the way burn victims heal

Cutiss CEO Daniela Marino is funneling her bold personality and expertise in regenerative medicine into a startup developing bioengineered skin grafts.

By Alexandra Pecci • May 9, 2023

How Immunocore’s Bahija Jallal embraced the ‘a-ha’ moment of promising science

The biotech CEO is bullish on the company’s pioneering T cell receptor platform and innovating new immunology-based treatments.

By Taren Grom • May 5, 2023

Woman of the Week: Jazz Pharmaceuticals’ Neena Patil

Patil’s dual interests in healthcare and law are at the intersection of her C-suite role.

By Taren Grom • May 3, 2023

A CEO’s quest to solve a 400-year-old medical mystery — and he’s also a patient

The CEO of Ventoux Biosciences has the disease that his company is aiming to treat, and it's driving him to find better medications.

By Taren Grom • May 1, 2023

Emalex aims at a first-in-class breakthrough for Tourette syndrome

With its phase 3 candidate, the biotech believes it can move the field beyond antipsychotics to a more effective approach.

By Kelly Bilodeau • May 1, 2023

5 minutes with — DTRA’s Dr. Amir Kalali

An industry veteran, innovator and curator, Dr. Amir Kalali discusses the high points of his career and his go-to productivity hack.

By Taren Grom • April 28, 2023

Scientists could finally be closing in on a ‘pill’ for men

Drug developers have tried — and failed — to create a male contraceptive for decades. Now, one group of scientists might be on the verge of success.

By Kelly Bilodeau • April 26, 2023